- Home
- UXIN vs GHRS Comparison
UXIN vs GHRS Comparison
Compare UXIN & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UXIN
- GHRS
- Stock Information
- Founded
- UXIN 2011
- GHRS 2018
- Country
- UXIN China
- GHRS Ireland
- Employees
- UXIN N/A
- GHRS N/A
- Industry
- UXIN Business Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- UXIN Consumer Discretionary
- GHRS Health Care
- Exchange
- UXIN Nasdaq
- GHRS Nasdaq
- Market Cap
- UXIN 721.6M
- GHRS 774.1M
- IPO Year
- UXIN 2018
- GHRS 2021
- Fundamental
- Price
- UXIN $3.44
- GHRS $12.64
- Analyst Decision
- UXIN
- GHRS Strong Buy
- Analyst Count
- UXIN 0
- GHRS 8
- Target Price
- UXIN N/A
- GHRS $30.63
- AVG Volume (30 Days)
- UXIN 233.0K
- GHRS 192.3K
- Earning Date
- UXIN 09-23-2025
- GHRS 11-13-2025
- Dividend Yield
- UXIN N/A
- GHRS N/A
- EPS Growth
- UXIN N/A
- GHRS N/A
- EPS
- UXIN 0.94
- GHRS N/A
- Revenue
- UXIN $300,239,165.00
- GHRS N/A
- Revenue This Year
- UXIN N/A
- GHRS N/A
- Revenue Next Year
- UXIN N/A
- GHRS N/A
- P/E Ratio
- UXIN $3.55
- GHRS N/A
- Revenue Growth
- UXIN 58.48
- GHRS N/A
- 52 Week Low
- UXIN $1.46
- GHRS $6.00
- 52 Week High
- UXIN $7.84
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- UXIN 50.50
- GHRS 46.67
- Support Level
- UXIN N/A
- GHRS $11.83
- Resistance Level
- UXIN $3.64
- GHRS $13.37
- Average True Range (ATR)
- UXIN 0.26
- GHRS 0.74
- MACD
- UXIN -0.12
- GHRS -0.07
- Stochastic Oscillator
- UXIN 92.38
- GHRS 38.41
About UXIN Uxin Limited ADS
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.